Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

6(75.0%)

Phase 3

1(12.5%)

Phase 1

1(12.5%)

8Total

Phase 2(6)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05819658Phase 2Completed

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

Role: lead

NCT06235775Phase 2Completed

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Role: lead

NCT06625710Phase 1Completed

Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects

Role: lead

NCT05189210Phase 2Completed

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

Role: lead

NCT04032067Phase 3Completed

Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

Role: lead

NCT02855892Phase 2Completed

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

Role: lead

NCT03959553Phase 2Withdrawn

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

Role: lead

NCT03184467Phase 2Completed

Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

Role: lead

All 8 trials loaded